Yao, J.C., Fazio, N., Singh, S., et al. (2016) Everolimus for the Treatment of Advanced, Non-Functional Neuroendocrine Tumours of the Lung or Gastrointestinal Tract (RADIANT-4): A Randomised, Placebo-Controlled, Phase 3 Study. The Lancet, 387, 968-977.
https://doi.org/10.1016/S0140-6736(15)00817-X

has been cited by the following article:

• TITLE: Radical Operation and Everolimus Therapy for Rectal Neuroendocrine Tumor with Liver Metastases: A Case Report with Review of the Literature

  AUTHORS: Jiaqi Xu, Yujie Cui, Xinfeng Huang, Yongbo Meng, Jian Xin, Yong Cheng

  KEYWORDS: Rectal Neuroendocrine Tumor, Liver Metastases, Everolimus, Radical Operation

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.9 No.9, September 17, 2020

  ABSTRACT: Neuroendocrine tumors (NETs) are often misdiagnosed because they can involve any part of the body and have non-specific symptoms. Here, we report a case of a 39-year-old man with rectal neuroendocrine tumor (RNET) and hepatic metastases treated with a combination of radical surgery and Everolimus therapy. The patient complained of abdominal distension, pain, and constipation of one month duration. Enhanced CT scan of the abdomen, colonoscopy and Biopsy findings confirmed the diagnosis of rectal neuroendocrine tumor. As the anatomical structures were clear and the masses seemed to be resectable, we decided to initiate treatment with radical operation and Everolimus therapy. The patient has responded well to the treatment with no evidence of recurrence after 4 years of follow-up. This case is interesting because of the rarity of this neoplasm and its initial misdiagnosis as a giant hepatic carcinoma (hepatoma). It also demonstrates that a combination of curative surgical resection and Everolimus is a good option in a patient with large colorectal neuroendocrine tumors and massive hepatic metastases.